Brief CorrespondenceAssociation Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
References (10)
- et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) - et al.
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Lancet Oncol
(2013) - et al.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol
(2015) - et al.
New guidelines to evaluate the response to treatment in solid tumors
J Natl Cancer Inst
(2000) - et al.
The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer
J Clin Oncol
(2015)
Cited by (14)
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
2017, Clinical Genitourinary CancerCitation Excerpt :Objective changes by RECIST may warrant serious consideration even in mCRPC because body imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is required more frequently and hence is detecting measurable tumors in mCRPC.9 Recent studies have discovered the association of measurable disease changes by World Health Organization criteria and RECIST 1.0 and 1.1 changes with overall survival (OS) in men with mCRPC receiving docetaxel-based chemotherapy.10,11 This study was undertaken to validate the association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel-based chemotherapy in the Southwest Oncology Group (SWOG) S0421 trial.12
Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer
2017, Clinical Genitourinary CancerCitation Excerpt :If our hypothesis is proven, measurable changes might need to be reconsidered as major end points in phase II trials of mCRPC seeking a signal of activity. Moreover, recent studies have shown the association of changes in measurable disease with survival in men receiving chemotherapy for mCRPC.5,6 To substantiate our hypothesis, we analyzed phase III trials of mCRPC to systematically quantitate the proportion of mCRPC with measurable disease.
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
2017, Critical Reviews in Oncology/HematologyCitation Excerpt :In a review of a cohort of patients who received AR axis targeted drugs for CRPC at two major French cancer centers, the previous duration of response to ADT was found to be a predictor of sensitivity to next generation AR axis targeted drugs in patients with metastatic CRPC (Loriot et al., 2015). The association between Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and 1.1 changes and OS in patients with metastatic CRPC from the control arms of the VENICE and MAINSAIL phase 3 trials, respectively, receiving docetaxel, prednisone, and placebo was examined (Sonpavde et al., 2016b). Based on the finding of an association between changes in objectively measurable tumors according to RECIST and survival, a focus on RECIST changes should be considered during drug development to provide an objective signal of efficacy.
Drug development in prostate cancer: time to embrace RECIST?
2017, The Lancet OncologyRationale for Modernising Imaging in Advanced Prostate Cancer
2017, European Urology FocusCitation Excerpt :Finally, the duration of imaging responses is also reported to be highly prognostic. No response or shorter durations of response to abiraterone and docetaxel treatments using bone scans (BSs) and the size-based criteria (for soft tissue disease) are associated with worse OS [37,38]. These poorer prognosis patients, failing androgen axis–targeted therapies, may benefit from earlier treatment with nontargeted survival-prolonging combination therapies such as docetaxel and cabazitaxel while still asymptomatic, although this too remains controversial.
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer
2017, Clinical Genitourinary Cancer
- †
These authors contributed equally to this work.